Monopar Therapeutics Inc. (MNPR)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Christopher M. Starr Ph.D. | Co-Founder & Independent Executive Chairman of the Board | 200k | -- | 1952 |
| Dr. Chandler D. Robinson M.B.A., M.D., M.Sc., MBA, MSc | Co-Founder, CEO, President & Director | 1.14M | -- | 1984 |
| Mr. Andrew J. Cittadine M.B.A. | Chief Operating Officer | 542.54k | -- | 1972 |
| Mr. Quan Anh Vu | CFO, Principal accounting officer & Principal financial officer | -- | -- | 1969 |
| Dr. Patrice P. Rioux M.D., Ph.D. | Acting Chief Medical Officer | -- | -- | 1951 |
Monopar Therapeutics Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 14
Description
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, a clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Corporate Governance
Upcoming Events
May 12, 2025 at 12:30 PM UTC - May 22, 2025 at 12:30 PM UTC
Monopar Therapeutics Inc. Earnings Date
Recent Events
January 23, 2025 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission